How the ‘Grim Reaper Effect’ Keeps Government From Saving Lives

How the 'Grim Reaper Effect' Keeps Government From Saving Lives

Why curing diseases may not always favor federal budgets.

Last summer, I came across a report by the Congressional Budget Office titled 'Budgetary Effects of Policies That Would Increase Hepatitis C Treatment,' a title that piqued my interest due to my fascination with how such policies impact the budget.

The report unearthed a crucial insight for future government attempts to save American lives.

Hepatitis C is a severe viral infection with persistent effects that, if neglected, can cause substantial liver damage over many years, significantly increasing the incidence of cirrhosis and liver cancer.

In the 2010s, highly effective antiviral medications, proven to cure over 95% of chronic cases in trials, emerged in the pharmaceutical market. Although groundbreaking, these patented drugs are costly. By 2020, the price for an eight-to-twelve-week course ranged from $11,500 to $17,000.

The CBO assessed that the effectiveness of these drugs, combined with the immense cost of untreated hepatitis C cases, makes expanding treatment cost-effective. Increasing Medicaid patient treatments by double would raise federal spending by $4 billion over ten years but would save nearly $7 billion on complications from untreated cases.

This situation represents what could be termed a budgeting anomaly: a policy that not only saves lives but also cuts government expenses.

Interestingly, the report highlighted a broader fiscal implication: enhanced hepatitis C treatment might lead to longer lifespans and fewer disabilities, impacting the federal budget beyond direct health savings.

The concept is simple: curing hepatitis C allows patients to live longer, thus increasing the years they receive benefits such as Social Security and Medicare, potentially negating savings from treatments.

This phenomenon is dubbed the 'Grim Reaper effect.' The United States faces a significant deficit, coupled with generous senior benefits compared to those for children or working-aged adults—over five times more per senior than per child. Consequently, extending life expectancy, other factors being constant, could deepen budgetary burdens.

The enduring impact of this effect has been apparent with other health issues, notably cigarettes, and is likely to continue manifesting in different forms.

Economic Reflections: Cigarettes as a Case Study

Cigarettes serve as an early example of the longevity dilemma in fiscal planning.

Mass cigarette consumption in the U.S began only recently. By 1963, Americans were smoking over 4,000 cigarettes per capita annually, a leap driven by technology, milder tobacco, and aggressive advertising.

Despite a consistent high until the early '70s, cigarette use dramatically dropped, falling to 667 per adult by 2022, with less than 12% of Americans smoking.

The health risks of smoking are delayed, manifesting decades later, which led to peak smoking-related mortality in the late 20th century, unmatched by today's less-dependent youth.

Decades ago, research examined smoking's fiscal impact. Despite healthcare costs, smokers tend to save the government on non-health expenses, mainly through reduced pension and Medicare spending due to shorter life expectancy.

Reports from the '90s highlighted how these 'savings' arise from decreased payouts in social benefits. Malcolm Gladwell even pondered on how not smoking affected pension systems.

In 2012, CBO's analysis on smoking tax effects showed initial federal savings from decreased health expenditures outweighing prolonged Social Security and Medicare burdens from extended lifespans. However, projections indicated that in the long-term, these savings diminished.

Policies that promote health aren't always financially advantageous to strict budget considerations.

For instance, the 2022 Medicare Trustees adjusted the anticipated Hospital Insurance Trust Fund exhaustion date due to Covid-19 prematurely impacting high-cost Medicare beneficiaries, indirectly reducing immediate healthcare expenses.

Health economics often examines vast mortality's quirky fiscal offshoots, showcasing a grim facet of health policies concerning budgetary implications.

The Value of Preserving Life

Economic analysts and government agencies must transparently predict program costs over varying timelines, despite their cold cynicism.

When Social Security benefits rise with longevity, it frames a broader debate: advancing humane policies against fiscal prudence.

Sometimes, policies should prevail based on ethical merit, irrespective of immediate fiscal paybacks, much like investments in military or cultural institutions.

Expanding Hepatitis C treatment aligns with funding noble causes even if it's not entirely budget-neutral.

Congress should equip analysts with tools to evaluate both the positive fiscal contributions and the liabilities of increased longevity.

Longer life often translates to more earning years, subsequently boosting federal revenues through taxes—effects needing symmetric consideration.

The CBO often reserves employment and revenue effects for dynamic scoring, sparking debate over its infrequent application.

By incorporating 'population change' scoring, discerning impacts of life expectancy and immigration on workforce and revenues could refine fiscal projections.

America's enduring deficit inclination underscores each citizen as a fiscal liability, a circumstance going beyond moral discourse.

Resource allocation heavily favors the elderly, leading to misaligned priorities when contrasted with younger demographics or international counterparts.

There's no inevitable reason U.S. policy must prefer one demographic so heavily—it mathematically rationalizes a preference for youthful mortality from a purely fiscal lens.

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Posts